Antoinette Tan, MD
Wake Forest University Health Sciences · Atrium Health (formerly Carolinas HealthCare System) · Rutgers Cancer Institute of New Jersey
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Antoinette Tan, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:32 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06027268 · Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerWake Forest University Health Sciences · active not recruiting · Metastatic Triple-Negative Breast Cancer · principal investigator
- Ph1NCT04762901 · LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast CancerWake Forest University Health Sciences · withdrawn · Breast Cancer · principal investigator
- Ph2NCT03018080 · Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast CancerWake Forest University Health Sciences · completed · Breast - Female, Male Breast Cancer · principal investigator
- Ph2NCT02942355 · Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast CancerWake Forest University Health Sciences · active not recruiting · Female Breast Carcinoma, Breast Cancer · principal investigator
- Ph1/Ph2NCT00634634 · Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast CancerRutgers, The State University of New Jersey · completed · Metastatic Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.